Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

GEN:DC

586.000 DKK 8.500 1.47%

As of 08:06:34 ET on 05/26/2015.

Snapshot for Genmab A/S (GEN)

Open: 575.000 Day's Range: 567.000 - 589.500 Volume: 278,379
Previous Close: 577.500 52wk Range: 204.800 - 597.500 1-Yr Rtn: +178.52%

Stock Chart for GEN

No chart data available.
  • GEN:DC 586.000
  • 1D
  • 1M
  • 1Y
577.500
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 79.8906
Estimated P/E(12/2015) 103.5277
Relative P/E vs. KFX 2.9541
Earnings Per Share (DKK) (ttm) 7.3100
Est. EPS (DKK) (12/2015) 5.6410
Est. PEG Ratio 2.1532
Market Cap (M DKK) 34,291.02
Shares Outstanding (M) 58.72
30 Day Average Volume 318,623
Price/Book (mrq) 13.1063
Price/Sale (ttm) 47.4712
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/11/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil